Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT ID: NCT03645187
Last Updated: 2021-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
50 participants
INTERVENTIONAL
2018-08-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
NCT00064181
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer
NCT03487939
Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon
NCT00085163
Intensified Chemotherapy in CRC After Resection of Liver Metastases
NCT00208260
The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment
NCT03130634
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FOLFERI
FOLFERI regien
FOLFERI
FOLFERI regimen
FOLFERI and celecoxib
FOLFERI and celecoxib
Folferi and celecoxib
Folferi regimen and celecoxib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FOLFERI
FOLFERI regimen
Folferi and celecoxib
Folferi regimen and celecoxib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* other malignancy
* H pylori infection
* thromboembolism
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
PhDTropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarek M Mostafa, Prof
Role: PRINCIPAL_INVESTIGATOR
Clinical pharmacy Department- Tanta University
Mohamed Alm El-din, prof
Role: STUDY_DIRECTOR
Clinical Oncology - Tanta University
Amira Roushdy, Msc
Role: STUDY_DIRECTOR
Clinical pharmacy Department- Tanta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amira Roushdy
Tanta, Elgharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
amira roushdy, msc
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Mostafa TM, Alm El-Din MA, Rashdan AR. Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: A randomized controlled clinical study. Saudi Med J. 2022 Jan;43(1):37-44. doi: 10.15537/smj.2022.43.1.20210574.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
celecoxib
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.